Definitive Contract 75N91023C00014

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

<p>The National Cancer Institute (NCI) awarded a $196,192 Firm Fixed Price SBIR Phase I contract to Gencia Corporation, a minority-owned limited liability company. The contract aims to analyze the impact of the compound rhtFam on the mitochondrial activity and apoptotic potential of the MCF-7 breast cancer cell line. The contract was set aside for small businesses. No additional subcontractors were mentioned.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Transgenex Nanobiotech Inc. The contract is for the development of novel therapeutic agents that target cancer, under SBIR Topic 326. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $1,474,849.83 and an ultimate completion date of July 31, 2019. Transgenex Nanobiotech Inc. is a minority-owned, for-profit...

This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...

<p>The National Cancer Institute awarded a $224,999.00 Firm Fixed Price definitive contract to Transgenex Nanobiotech Inc., a minority-owned for-profit business, to develop anti-NPRA inhibitors targeting cancer stem cells in tumoroids. The contract has a completion date of September 11, 2015 and is not associated with any set-aside designation. Transgenex Nanobiotech Inc. has received previous federal contract and grant awards, with the most recent contract award on February 1, 2017.</p>

<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a &quot;fibrous scaffold-induced spheroids mimicking TME&quot; solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>

This firm fixed price definitive contract was awarded by the National Institutes of Health National Cancer Institute to Senti Biosciences, Inc., a self-certified small disadvantaged business, for $1,999,993. The contract addresses Topic 414 from the fiscal year 2021 Small Business Innovation Research Program solicitation issued by the Department of Health and Human Services, which sought proposals for synthetic biology gene circuits for cancer therapy. The place of performance is South San...

This is a $355,000 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to Vcreate, Inc., a minority-owned, self-certified small disadvantaged business. The contract is a Phase I Small Business Technology Transfer (STTR) award that supports the development of T-cell receptors for treating pediatric acute myeloid leukemia. The contract was set aside for small businesses and aims to demonstrate technical...

This federal contract award, valued at $22,825.00, was issued by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH). The contract was awarded to Synthego Corporation, a self-certified small disadvantaged business and manufacturer of gene editing products based in Redwood City, California. The contract is for the delivery of KNOCKIN-SMALL, CELL CLONE, IPSC, SYNTHEGO SUPPLIED services, which likely support NCATS'...